Report
Merck and Moderna explore cancer vaccine uses beyond certain melanoma patients
STAT reports the companies are preparing to seek approval after announcing results from a large Phase 3 melanoma trial.
TLDR
STAT reports that Merck and Moderna are preparing to file their personalized mRNA cancer vaccine for approval. The companies announced in August that a large Phase 3 trial found it significantly delayed cancer recurrence and the development of metastatic disease in melanoma patients. They are now looking to show it can help patients beyond certain people with melanoma.
Combined views
1.2K
1 Source, first seen ago
